IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Gareth Sheridan, Co-Founder and CEO of Nutriband Inc. (NASDAQ: NTRB), a company engaged in the development of a portfolio of transdermal pharmaceutical products.
During the interview, Sheridan provided an introduction to Nutriband’s business model.
“We’re a pharmaceutical company specifically focused on transdermal technology… Our core focus is on a segment of the industry that has been overlooked and underrepresented for quite some time now – adequate pain management in the transdermal space. We’re all familiar and aware of the opiate scandals over the last 10 years and the fallout from that. It resulted in a very negative opiate stigma surrounding all of pain management, but the real fallout was actually a lack of adequate care for pain patients. We’re tackling this head-on with our AVERSA™ technology.”
“It is a platform tech that we’ve developed internally that can be applied to any pain patch medication with the goal of making them very difficult to abuse. Because of that, we’re also making these medications accessible to patients who have had their access cut in recent years… Our first application for AVERSA is a fentanyl patch. Fentanyl is a scary word in a lot of people’s vocabulary, but, when used correctly, fentanyl is a very effective pain medication… Unfortunately, because of the fallout from the opiate scandals we’ve seen in recent years, these types of products have been faced with a major reluctance when it comes to prescribers, insurance companies, and payers. Nobody wants to deal with the liability issues associated with these products.”
“You saw companies actually getting out of the space and moving on, but the people who felt the fallout from this were actually the pain patient themselves. Prescription rates are down an astronomical number since their height in 2016, when fentanyl patches, for example, were about a $4 billion a year market. They’re under $1 billion a year now in terms of market size, but the patient population requiring access to these medications has not reduced by 75%. We’re looking at a massive disconnect between adequate management and adequate care for patients on prescription rates. That’s something that we’ll tackle head-on with our AVERSA technology.”
Join IBN’s Carmel Fisher and Gareth Sheridan, Co-Founder and CEO of Nutriband, to learn more about the company’s development pipeline, as well as the unique ways AVERSA helps address abuse of pain medication.
To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com
The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
About Nutriband Inc.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
For more information, visit the company’s website at www.Nutriband.com
About IBN
IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.